Patents by Inventor Christopher Lawrence Moore

Christopher Lawrence Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11414677
    Abstract: Disclosed herein are methods of performing continuous directed evolution in complex biological systems, including metazoan cells. These methods include the infection of engineered, non-naturally occurring metazoan cells with engineered, non-naturally occurring DNA viruses. The generation of infectious viruses that can infect new cells depends on the evolution of a gene of interest which is driven by an error-prone adenoviral polymerase. Also disclosed herein, are the compositions of engineered, non-naturally occurring metazoan cells and engineered, non-naturally occurring DNA viruses that function as components in the continuous directed evolution methodologies.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: August 16, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Matthew D. Shoulders, Chet Berman, Christopher Lawrence Moore, Louis John Papa, Samuel Joseph Hendel
  • Publication number: 20210246426
    Abstract: The present disclosure relates to engineered erythroid cells and enucleated cells that include one or more of exogenous HLA-G polypeptides, exogenous immunogenic polypeptides, and exogenous coinhibitory polypeptides wherein the cells are capable of inducing immune tolerance and/or reducing immune response to the exogenous immunogenic polypeptides when administered to a subject.
    Type: Application
    Filed: June 1, 2020
    Publication date: August 12, 2021
    Applicant: Rubius Therapeutics, Inc.
    Inventors: Regina Sophia Salvat, Christopher Lawrence Moore, Abdulsalam Shaaban
  • Publication number: 20200291355
    Abstract: The present disclosure provides customizable enucleated erythroid cells or enucleated cells that can be engineered to include, on their surface, a loadable exogenous antigen-presenting polypeptide, wherein the loadable exogenous antigen-presenting polypeptide comprises one or more amino acid substitutions. In some embodiments, the one or more amino acid substitutions stabilize the loadable exogenous antigen-presenting polypeptide on the cell surface. In some embodiments, the loadable exogenous antigen-presenting polypeptide is stabilized on the cell surface in the absence of a polypeptide bound to the loadable exogenous antigen-presenting polypeptide. In some embodiments, the loadable exogenous antigen-presenting polypeptide comprises an exogenous displaceable polypeptide bound to the loadable exogenous antigen-presenting polypeptide. In some embodiments, the loadable exogenous antigen-presenting polypeptide is stabilized on the cell surface upon release of the displaceable polypeptide.
    Type: Application
    Filed: February 20, 2020
    Publication date: September 17, 2020
    Inventors: Tiffany Fen-Yi Chen, Thomas Joseph Wickham, Christopher Lawrence Moore, Shamael Rabia Dastagir, Douglas Charles Mclaughlin, Regina Sophia Salvat, Alex Richard Nanna
  • Publication number: 20190309284
    Abstract: Disclosed herein are methodologies and kits for dynamic targeted hypermutation that harness the enzymatic activity of a polynucleic acid-binding protein fused to a nucleobase-editing enzyme to specifically target mutations across a region of interest. These methodologies and kits facilitate the rapid creation of diverse DNA libraries in vivo or in vitro.
    Type: Application
    Filed: March 19, 2019
    Publication date: October 10, 2019
    Applicant: Massachusetts Institute of Technology
    Inventors: Matthew D. Shoulders, Louis John Papa, Christopher Lawrence Moore
  • Publication number: 20190153472
    Abstract: Disclosed herein are methods of performing continuous directed evolution in complex biological systems, including metazoan cells. These methods include the infection of engineered, non-naturally occurring metazoan cells with engineered, non-naturally occurring DNA viruses. The generation of infectious viruses that can infect new cells depends on the evolution of a gene of interest which is driven by an error-prone adenoviral polymerase. Also disclosed herein, are the compositions of engineered, non-naturally occurring metazoan cells and engineered, non-naturally occurring DNA viruses that function as components in the continuous directed evolution methodologies.
    Type: Application
    Filed: October 26, 2018
    Publication date: May 23, 2019
    Applicant: Massachusetts Institute of Technology
    Inventors: Matthew D. Shoulders, Chet Berman, Christopher Lawrence Moore, Louis John Papa, Samuel Joseph Hendel